Unique ID issued by UMIN | UMIN000010309 |
---|---|
Receipt number | R000012064 |
Scientific Title | The effect of enoxaparin with cilostazol for prevention of venous thromboembolism after total knee and hip arthroplasty |
Date of disclosure of the study information | 2013/03/23 |
Last modified on | 2015/06/13 12:54:22 |
The effect of enoxaparin with cilostazol for prevention of venous thromboembolism after total knee and hip arthroplasty
The effect of cilostazol for prevention of venous thromboembolism after arthroplasty
The effect of enoxaparin with cilostazol for prevention of venous thromboembolism after total knee and hip arthroplasty
The effect of cilostazol for prevention of venous thromboembolism after arthroplasty
Japan |
deep-vein thrombosis
Orthopedics |
Others
NO
his study is conducted the effect of enoxaparin with cilostazol for prevention of venous thromboembolism after total knee and hip arthroplasty
Efficacy
The next day of surgery is defined as day 1.Deep-vein thrombosis is assessed on day 14 by mean of ultrasonography
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Pseudo-randomization
2
Prevention
Medicine |
Patients are assigned to receive twice-daily injection of enoxaparin sodium, in a 20-mg dose. Enoxaparin is initiated 24 to 36 hours after surgery until day 14.
Patients are assigned to receive twice-daily injection of enoxaparin sodium, in a 20-mg dose. Enoxaparin is initiated 24 to 36 hours after surgery until day 14. And patients are also received once-daily oral cilostazol, in a 50-mg tablet 3 days before surgery , in two 50-mg tablets 2 days before surgery and are given two 50-mg tablets again 24 to 36 hours after wound closure. Then patients are received twice-daily cilostazol, in a 100-mg tablet 2 days after surgery until day 14.
20 | years-old | <= |
Not applicable |
Male and Female
Patients are eligible for the study if they were 20 years of age or older and are scheduled for total knee arthroplasty or total hip arthroplasty.
We exclude patients with active bleeding or a high risk of bleeding that contraindicated the use of low-molecular-weight heparin and patients with any contraindication to the
use of enoxaparin or cilostazol.
Other exclusion criteria include conditions clinically significant compromised renal function, acute endocarditis, heparin induced thrombocytopenia, congestive heart failure, and pregnancy or breast-feeding.
50
1st name | |
Middle name | |
Last name | Kato yosiharu |
Tokyo Women's Medical University
Department of Orthopedic surgery
8-1 Kawada-cho Shinjuku-ku Tokyo
03-3353-8111
1st name | |
Middle name | |
Last name | morita yuji |
Tokyo Women's Medical University
Department of Orthopedic surgery
8-1 Kawada-cho Shinjuku-ku Tokyo
03-3353-8111
morita@ort.twmu.ac.jp
Department of orthopedic surgery, Tokyo women's medical university
None
Self funding
Japan
NO
2013 | Year | 03 | Month | 23 | Day |
Published
Completed
2011 | Year | 10 | Month | 13 | Day |
2011 | Year | 11 | Month | 01 | Day |
2014 | Year | 01 | Month | 29 | Day |
2015 | Year | 04 | Month | 30 | Day |
2015 | Year | 04 | Month | 30 | Day |
2015 | Year | 04 | Month | 30 | Day |
2013 | Year | 03 | Month | 23 | Day |
2015 | Year | 06 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012064
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |